We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




ECOFF and AST Determined for Invasive Non-Typhoidal Salmonella

By LabMedica International staff writers
Posted on 04 Jul 2022

Invasive non-typhoidal Salmonella (iNTS) are a primary cause of bloodstream infections in low-resource settings (LRS). More...

The global burden has been estimated at 535,000 iNTS cases and 77,500 deaths per year. In sub-Saharan Africa, most iNTS are multidrug-resistant and non-susceptibility to third generation cephalosporins and fluoroquinolones has emerged.

In this context, azithromycin is an important candidate for oral iNTS treatment. Azithromycin is effective to treat typhoid fever and has, despite missing clinical efficacy data, been recommended for (switch to) oral iNTS treatment. Nevertheless, there are no international guidelines on azithromycin antibiotic susceptibility testing (AST) and interpretation for iNTS.

Clinical Scientists at the Institute of Tropical Medicine (Antwerp, Belgium) used EUCAST ECOFFinder to determine the minimum inhibitory concentrations (MIC; obtained by broth microdilution) epidemiological cut-off (ECOFF) and corresponding disk zone diameters of 515 iNTS from blood cultures in DR Congo, Burkina Faso, Rwanda, and Cambodia. Transferable resistance mechanisms were determined by polymerase chain reaction.

MIC values were determined with the semi-automated Sensititre AST System (Sensititre Nephelometer, AIM automated inoculator & Vizion digital MIC viewing system; Thermo Fisher Scientific, Waltham, MA, USA), with customized, single lot dry Sensititre plates (serial twofold azithromycin dilutions: 0.125 – 512 mg/L. For disk diffusion, they used 15 μg azithromycin disks from different brands (Oxoid/Thermo Fisher; BD, Becton, Dickinson and Company, Franklin Lakes, NJ, USA; Rosco, Taastrup, Denmark; Liofilchem, Abruzzi, Italy) and commercially prepared Mueller-Hinton agar plates (BD) for 161 wild and 198 non-wild type iNTS.

The investigators reported that azithromycin MIC ECOFF was 16 mg/L corresponding to a 12mm zone diameter; mphA was detected in 192/197 non-wild and 0/47 wild type iNTS. Categorical agreement was excellent (≥98%) for all methods. Essential agreement was very good for agar dilution (>90%), but moderate for gradient tests (MIC80%: 52 – 71% and MIC100%: 72 – 91%). Repeatability was good for all methods/brands. Inter-reader agreement was high for broth microdilution and agar dilution (all ≤1 twofold dilution difference) and disk diffusion (>96% ≤3mm difference), but lower for gradient tests (MIC80% & MIC100%: 83 − 94% ≤1 twofold dilution difference).

The authors concluded that Azithromycin ECOFF of iNTS was 16 mg/L, i.e. equal to Salmonella Typhi. Disk diffusion is an accurate, precise, and user-friendly alternatives for agar dilution and broth microdilution. Reading gradient tests at 100% instead of 80% inhibition improved accuracy and precision. The study was published on June 20, 2022 in the journal Clinical Microbiology and Infection.

Related Links:
Institute of Tropical Medicine 
Thermo Fisher Scientific 
Becton, Dickinson and Company
Rosco
Liofilchem


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
New
Gold Member
Collection and Transport System
PurSafe Plus®
Gold Member
Rapid AKI Test
Acute Kidney Injury (AKI) Array (4-plex)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.